April 28, 2023
Allan Valmonte, M.B.A., former Executive Director, Program Management Office (PMO) at Taysha Gene Therapies, joins OncoSpherix with over 25 years of program/portfolio management and clinical operations experience in the biotechnology and pharmaceutical industry.
Atlanta, GA – April 28, 2023 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors in a variety of cancer indications, today announces the latest addition to their executive leadership team with the appointment of Allan Valmonte, M.B.A. as Vice President of Business Operations. Mr. Valmonte brings more than 25 years of program/portfolio management and clinical operations experience. He will be responsible for overseeing program/portfolio and alliance management and will report to Margaret K. Offermann, M.D., Ph.D., OncoSpherix’s President, CEO, and member of the Board of Directors.
CEO of OncoSpherix, Margaret K. Offermann, M.D., Ph.D. states, ”OncoSpherix is very fortunate to have Mr. Valmonte as part of our management team. His knowledge combined with his experiences and interpersonal qualities will accelerate OncoSpherix’s ability to advance its promising therapeutics for patients suffering from many forms of cancer.”
Mr. Valmonte joins OncoSpherix with more than 25 years of experience in program/portfolio management and clinical operations within the biotechnology and pharmaceutical industry. Most recently, he served as Executive Director, PMO at Taysha Gene Therapies, where he oversaw the creation and implementation of the PMO infrastructure to support portfolio and program management activities across Taysha’s therapeutic franchises. Prior to joining Taysha, Mr. Valmonte served as Executive Director, Program Strategy – Rare Disease and Pediatrics at Premier Research, Ltd, a full-service CRO, where he served as principal strategist during the planning and design phases of new business opportunities as well as primary contact with numerous sponsor companies within the rare disease, pediatrics, gene therapy development space. He previously held various management positions, with increasing responsibility in program management at Rocket Pharmaceuticals, and clinical operations at Abeona Therapeutics, Galena Biopharma, and KAI Pharmaceuticals.
Mr. Valmonte serves as an adjunct professor within the Haub School of Business at Saint Joseph’s University in Philadelphia, PA. Mr. Valmonte holds a B.A. in Psychology from California State University, Hayward, and an M.B.A. with honors from Saint Joseph’s University in Philadelphia, PA.
About OncoSpherix:
OncoSpherix, Inc., based in Atlanta, GA, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supplies, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candidate has been shown in mouse models to reduce primary tumor growth, inhibit metastasis, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). OncoSpherix intends to advance its lead candidate in one or more of these indications, in combination with agents that show therapeutic synergy while being well-tolerated.as part of the combination.
Company Contact:
Allan Valmonte
VP of Business Operations
valmonte@oncospherix.com
Source: OncoSpherix, Inc.